WO2001005425A3 - Combined preparations comprising daunorubicin derivatives and her2 antibodies - Google Patents
Combined preparations comprising daunorubicin derivatives and her2 antibodies Download PDFInfo
- Publication number
- WO2001005425A3 WO2001005425A3 PCT/EP2000/006540 EP0006540W WO0105425A3 WO 2001005425 A3 WO2001005425 A3 WO 2001005425A3 EP 0006540 W EP0006540 W EP 0006540W WO 0105425 A3 WO0105425 A3 WO 0105425A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- her2 antibodies
- combined preparations
- daunorubicin
- daunorubicin derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00945903A EP1200098A2 (en) | 1999-07-20 | 2000-07-10 | Combined preparations comprising daunorubicin derivatives and anti her2 antibodies |
JP2001510479A JP2003504413A (en) | 1999-07-20 | 2000-07-10 | Combination preparation containing an antitumor substance |
AU59839/00A AU5983900A (en) | 1999-07-20 | 2000-07-10 | Combined preparations comprising antitumor agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9917012.8A GB9917012D0 (en) | 1999-07-20 | 1999-07-20 | Combined preparations comprising antitumor agents |
GB9917012.8 | 1999-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001005425A2 WO2001005425A2 (en) | 2001-01-25 |
WO2001005425A3 true WO2001005425A3 (en) | 2001-05-17 |
Family
ID=10857596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/006540 WO2001005425A2 (en) | 1999-07-20 | 2000-07-10 | Combined preparations comprising daunorubicin derivatives and her2 antibodies |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1200098A2 (en) |
JP (1) | JP2003504413A (en) |
AU (1) | AU5983900A (en) |
GB (1) | GB9917012D0 (en) |
WO (1) | WO2001005425A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698265A (en) | 2000-05-19 | 2012-10-03 | 杰南技术公司 | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
GB0114654D0 (en) * | 2001-06-15 | 2001-08-08 | Pharmacia & Upjohn Spa | Anti-tumor compound |
ES2710439T3 (en) | 2005-01-21 | 2019-04-25 | Genentech Inc | Fixed dosage of HER antibodies |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
ES2572728T3 (en) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Bispecific anti-HER antibodies |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
PL2536748T3 (en) | 2010-02-18 | 2015-01-30 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
JP5766296B2 (en) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components |
WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
JP2015500638A (en) | 2011-11-30 | 2015-01-08 | ジェネンテック, インコーポレイテッド | ERBB3 mutations in cancer |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
JP2015514710A (en) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment of HER3 inhibitors |
CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
US10167342B2 (en) | 2016-08-29 | 2019-01-01 | Fazel Shokri | Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment |
PT110526B (en) | 2018-01-26 | 2021-02-04 | Univ Nova De Lisboa | ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS |
EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
JP2024529381A (en) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | Duplex Body |
AR127568A1 (en) | 2021-11-03 | 2024-02-07 | Affimed Gmbh | CD16A BISPECIFIC LIGANDS |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
EP0328147A2 (en) * | 1988-02-11 | 1989-08-16 | Bristol-Myers Squibb Company | Anthracycline immunoconjugates having a novel linker and methods for their production |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
WO1999031140A1 (en) * | 1997-12-12 | 1999-06-24 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2000044225A1 (en) * | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu |
WO2000061185A1 (en) * | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A | Docetaxel in combination with rhumab her2 for the treatment of cancers |
WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
-
1999
- 1999-07-20 GB GBGB9917012.8A patent/GB9917012D0/en not_active Ceased
-
2000
- 2000-07-10 AU AU59839/00A patent/AU5983900A/en not_active Abandoned
- 2000-07-10 EP EP00945903A patent/EP1200098A2/en not_active Withdrawn
- 2000-07-10 WO PCT/EP2000/006540 patent/WO2001005425A2/en not_active Application Discontinuation
- 2000-07-10 JP JP2001510479A patent/JP2003504413A/en not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5677171A (en) * | 1988-01-12 | 1997-10-14 | Genentech, Inc. | Monoclonal antibodies directed to the HER2 receptor |
EP0328147A2 (en) * | 1988-02-11 | 1989-08-16 | Bristol-Myers Squibb Company | Anthracycline immunoconjugates having a novel linker and methods for their production |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
WO1999031140A1 (en) * | 1997-12-12 | 1999-06-24 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
WO2000044225A1 (en) * | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu |
WO2000061185A1 (en) * | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A | Docetaxel in combination with rhumab her2 for the treatment of cancers |
WO2000069460A1 (en) * | 1999-05-14 | 2000-11-23 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Non-Patent Citations (1)
Title |
---|
BASELGA J ET AL: "HER2 Overexpression and Paclitaxel sensitivity in breast cancer: Therapeutic implications", ONCOLOGY,CH,S. KARGER AG, BASEL, vol. 11, no. 3, SUPPL. 02, March 1997 (1997-03-01), pages 43 - 48, XP002100077, ISSN: 0030-2414 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
Also Published As
Publication number | Publication date |
---|---|
AU5983900A (en) | 2001-02-05 |
EP1200098A2 (en) | 2002-05-02 |
WO2001005425A2 (en) | 2001-01-25 |
GB9917012D0 (en) | 1999-09-22 |
JP2003504413A (en) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001005425A3 (en) | Combined preparations comprising daunorubicin derivatives and her2 antibodies | |
AU5365296A (en) | Human monoclonal antibody against lung carcinoma | |
CA2249320A1 (en) | Glycosylated humanized b-cell specific antibodies | |
WO1997019111A3 (en) | Monoclonal antibodies anti-cd6 and their uses | |
HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
ZA200110263B (en) | Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies. | |
DK0586002T3 (en) | Monoclonal antibodies that recognize the epidermal growth factor receptor, its cells and methods, and preparations thereof | |
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
CA2072249A1 (en) | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane | |
IL214084A (en) | Kit comprising humanized anti-erbb2 antibodies and instructions for their use to treat breast cancer | |
AU1704099A (en) | Monoclonal human natural antibodies | |
IS8950A (en) | Monoclonal antibody against human CTLA-4. | |
AU5047800A (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
WO1997046589A3 (en) | Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods | |
AU6266899A (en) | Methods for producing human tumor antigen specific antibodies | |
AU2001256325A1 (en) | Human and humanized fap-alpha-specific antibodies | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
AU2407899A (en) | Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it | |
AU6702998A (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
AU5441000A (en) | Human monoclonal antibody | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
AU2003215381A1 (en) | EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER | |
AU4373197A (en) | Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof | |
ZA941645B (en) | Antibodies specifically reactive against human prostate specific antigen. | |
AU1809695A (en) | Tumor associated monoclonal antibody 123av16 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000945903 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945903 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945903 Country of ref document: EP |